Case report

Open Access

Herpes Zoster Ophthalmicus Following Covid-19 Vaccination: A Case Report

Elisse Park MD, Christian Mays MD, Sneha Konda MD and Christopher Leffler MD

Virginia Commonwealth University Department of Ophthalmology, Richmond, VA, USA

ABSTRACT

Herpes zoster ophthalmicus is a manifestation of herpes zoster infection, typically with eye symptoms. We report a case of herpes zoster ophthalmicus in a patient who had recently received the Johnson & Johnson COVID-19 vaccine. There have been other case reports of HZO in patients who recently got the same vaccine.

*Corresponding author

Elisse Park MD, Virginia Commonwealth University Department of Ophthalmology, Richmond, VA, USA. E-mail: elisse.park@vcuhealth.org

Received: August 23, 2021; **Accepted:** August 28, 2021; **Published:** September 02, 2021

Introduction

Herpes Zoster Ophthalmicus (HZO) is an uncommon manifestation of hHerpes zoster which affects the ophthalmic nerve. Ophthalmic manifestations of HZO include: keratitis, dermatitis, conjunctivitis, trabeculitis, retinitis, choroiditis, conjunctivitis, scleritis, episcleritis, and cranial nerve palsies.

Case Presentation

We report a case of herpes zoster ophthalmicus in a patient who had recently received the Johnson & Johnson COVID-19. A 57-year-old woman with history of hypertension and asthma was referred to the eye clinic due to concern for herpes zoster near the right eye. The patient received the Johnson & Johnson COVID-19 vaccine 5 days prior to the visit. She reports that she began having eye pain 2-3 days prior to the visit and then developed a rash. She denied a history of cancer, diabetes mellitus, radiation therapy, or other conditions associated with systemic immunosuppression.

The visual acuity with her current glasses was 20/100 in the right eye and 20/40 in the left eye. The eye pressure was 16 in the right eye and 16 in the left eye. There was a vesicular rash on the right side of the face in the V1 distribution, including the right upper eyelid. The conjunctiva and sclera of the right eye both eyes was mildly injected, while the left eye was white and quiet. The cornea of both eyes was clear. The anterior chamber of both eyes was deep and quiet. The posterior segment exam was normal for both eyes. The patient was started on acyclovir, -800 mg by mouth, 5 times daily.

The patient returned for follow up 7 days later. She felt that the rash was improving and that she was able to her open her eye more. Eye examination showed crusting of some of the vesicles (Figure 1). Her right cornea had a new epithelial defect and multiple punctate epithelial erosions (Figure 2). The patient was started on bacitracin ophthalmic ointment to the right eye and affected areas twice daily morning and night, with the option to use three times

daily on affected areas if more needed, and continued acyclovir.

Discussion

This patient received the Johnson & Johnson (J&J) vaccine While Pfizer and Moderna vaccines are made using mRNA to make a surface protein (known as “the spike”) to activate the immune system; J&J vaccine uses a viral vectored vaccine, an adenovirus, to make spike proteins which then triggers the immune system to create antibodies.

An observational study from Israel reported 6 cases of herpes zoster (HZ) after patients with autoimmune rheumatic diseases received the BNT162b2 mRNA COVID-19 vaccine (tozinameran, Pfizer) [1]. Additionally, there have been case reports of patients without known autoimmune conditions that have experienced a reactivation of herpes zoster described in literature in European journals of medicine and dermatology [2]. Although this correlation is new, it is not necessarily unexpected, as there are other cases of HZO reactivation with recent stress or immunomodulation, such as spaceflight, recent vaccinations against influenza, hepatitis A, or rabies [3-5].

Figure 1: Vesicular rash in right V1 distribution

Figure 2: Epithelial defect on right cornea

References

1. Furer V, Zisman D, Kibari A, Rimar D, Paran Y, et al. (2021) Herpes zoster following BNT162b2 mRNA Covid-19 vaccination in patients with autoimmune inflammatory rheumatic diseases: a case series. Rheumatology <https://doi.org/10.1093/rheumatology/keab345>.
2. Tessa I and Kluger N (2021) Ipsilateral herpes zoster after the first dose of BNT162b2 mRNA COVID-19 vaccine. J Eur Acad Dermatol Venereol. <https://doi.org/10.1111/jdv.17422>.
3. Eid E, Abdullah L, Kurban M, Abbas O (2021) Herpes zoster emergence following mRNA COVID-19 vaccine. J Med Virol. <https://doi.org/10.1002/jmv.27036>.
4. Walter R, Hartmann K, Fleisch F, Reinhart WH, Kuhn M (1999) Reactivation of herpesvirus infections after vaccinations? Lancet 6; 353-810.
5. Arnold N, Messaoudi I (2017) Herpes zoster and the search for an effective vaccine. Clin Exp Immunol 187:82-92.

Copyright: ©2021 Elisse Park, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.